| Bret Schaller, DPT | |
|
5485 Mooretown Rd Ste E, Williamsburg, VA 23188-2130 | |
| (757) 969-5200 | |
| (757) 969-5201 |
| Full Name | Bret Schaller |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 13 Years |
| Location | 5485 Mooretown Rd Ste E, Williamsburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245513050 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 2305207000 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apex Physical Therapy Llc | 2264783752 | 2 |
News Archive
ChemGenex Pharmaceuticals Limited and Hospira, Inc. announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex's product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).
Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.
Inter Press Service looks at the U.N. Human Rights Council's (HRC) endorsement of water and sanitation as a basic human right last week, and the reality that water and sanitation have remained two of the most neglected sub-texts of the eight Millennium Development Goals (MDGs) which came under scrutiny at the MDG summit in September.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
Although many blame the health law for all recent health care cost increases, trends that bump up the cost of care were in place before the law was enacted and are being driven up even more by routine costs, some say.
› Verified 3 days ago
| Provider Name | Apex Physical Therapy Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1184102394 PECOS PAC ID: 2264783752 Enrollment ID: O20180921002476 |
News Archive
ChemGenex Pharmaceuticals Limited and Hospira, Inc. announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex's product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).
Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.
Inter Press Service looks at the U.N. Human Rights Council's (HRC) endorsement of water and sanitation as a basic human right last week, and the reality that water and sanitation have remained two of the most neglected sub-texts of the eight Millennium Development Goals (MDGs) which came under scrutiny at the MDG summit in September.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
Although many blame the health law for all recent health care cost increases, trends that bump up the cost of care were in place before the law was enacted and are being driven up even more by routine costs, some say.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bret Schaller, DPT 5485 Mooretown Rd Ste E, Williamsburg, VA 23188-2130 Ph: (757) 969-5200 | Bret Schaller, DPT 5485 Mooretown Rd Ste E, Williamsburg, VA 23188-2130 Ph: (757) 969-5200 |
News Archive
ChemGenex Pharmaceuticals Limited and Hospira, Inc. announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex's product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).
Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.
Inter Press Service looks at the U.N. Human Rights Council's (HRC) endorsement of water and sanitation as a basic human right last week, and the reality that water and sanitation have remained two of the most neglected sub-texts of the eight Millennium Development Goals (MDGs) which came under scrutiny at the MDG summit in September.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
Although many blame the health law for all recent health care cost increases, trends that bump up the cost of care were in place before the law was enacted and are being driven up even more by routine costs, some say.
› Verified 3 days ago
Tidewater Physical Therapy, Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4125 Ironbound Rd, Ste 100, Williamsburg, VA 23188 Phone: 757-220-8383 Fax: 757-253-7833 | |
Tara Lee Perkins, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 111 Bulifants Blvd Ste A, Williamsburg, VA 23188 Phone: 757-564-7381 Fax: 757-564-7391 | |
Ann Degruy Scanlon, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 5700 Warhill Trl, Williamsburg, VA 23188 Phone: 757-912-2726 | |
D Russell Mosher, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 109 Bulifants Blvd, Suite B, Williamsburg, VA 23188 Phone: 757-229-9740 Fax: 757-345-6953 | |
Karen Mcpadden, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 5388 Discovery Park Blvd Ste 100, Williamsburg, VA 23188 Phone: 757-903-4230 Fax: 757-903-4231 | |
Scott Milliken, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 4125 Ironbound Rd Ste 100, Williamsburg, VA 23188 Phone: 757-220-8383 | |
Reach For Performance, Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 312 Lightfoot Rd, Suite J, Williamsburg, VA 23188 Phone: 757-258-1221 Fax: 757-258-7733 |